Can doctors trust AI to predict lung cancer outcomes?
NCT ID NCT06699615
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study asks 50 lung cancer doctors to review AI-generated explanations for patient prognosis and rate how trustworthy they seem. The goal is to see if a newer type of AI (neurosymbolic) is more trusted than standard methods. No patients are treated; the data is simulated. The results may guide future use of AI in cancer care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors trust AI tools that predict how lung cancer will progress, potentially improving decision-making.
- What could go wrong
- This is a small survey with simulated data, not a clinical trial testing a treatment. Results may not apply to real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19083, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?